Extensively drug-resistant tuberculosis in the UK: 1995 to 2007

I Abubakar,1 J Moore,1 F Drobniewski,1 M Kruijshaar,1 T Brown,1 M Yates,1 C Anderson,1 E G Smith,2 J Magee,3 M Lipman,4 J McMenamin,5 M Ruddy,6 J M Watson1

ABSTRACT

Background: The emergence of multidrug-resistant tuberculosis (MDRTB) and extensively drug-resistant tuberculosis (XDRTB) is a threat to global tuberculosis control. Limited information is, however, available on the outcome of XDRTB cases. This study describes the susceptibility to second- and third-line antituberculosis drugs among MDRTB cases and treatment outcome of identified XDRTB cases.

Method: The results of second-line antituberculosis drug susceptibility tests in the UK between January 1995 and December 2007 were retrospectively reviewed and clinicians contacted for treatment outcome of XDRTB cases. Participants included all 678 patients with culture-confirmed MDRTB in the UK. The main outcome measures were the proportion of isolates resistant to second-line antituberculosis drugs and treatment outcome for XDRTB cases.

Results: Among MDRTB isolates, levels of resistance to amikacin, capreomycin, ciprofloxacin, cycloserine, ethionamide and p-aminosalicylic acid (PAS) were 5.5, 3.4, 5.6, 5.1, 14.0 and 16.7%, respectively. Six XDRTB cases (0.9% of MDR cases) were identified during this period. Two further cases of XDRTB were reported in 2008. Five individuals with XDRTB died of tuberculosis within 3 years of diagnosis and three are still on treatment.

Conclusion: Levels of MDRTB remain low, and those of XDRTB very low, in this high income country. The case fatality ratio among XDRTB cases was high despite low levels of HIV co-infection.

The emergence of multidrug-resistant tuberculosis (MDRTB) and extensively drug-resistant tuberculosis (XDRTB) is a threat to global tuberculosis control. These forms of tuberculosis are difficult and expensive to treat and often associated with a poor clinical outcome.1,2 In the case of MDRTB, this relates to the loss of the highly potent antituberculosis drugs isoniazid, the drug with the strongest early bactericidal action against Mycobacterium tuberculosis complex, and rifampicin, which acts against bacilli that are no longer in the active phase of replication. Treatment options are fairly limited and associated with a variety of side effects.3 Although survival is improved by the administration of drugs to which the bacteria are susceptible,1,4 the development of resistance to second- and third-line drugs (especially fluoroquinolones and injectable agents) among cases with MDRTB further worsens the prognosis of these patients.2

The World Health Organization describes increasing levels of MDRTB globally.5 In the UK, the incidence of MDRTB has risen, although the magnitude of the increase is small.6 Here we describe the susceptibility to second- and third-line antituberculosis drugs among MDRTB cases in the UK between January 1995 and December 2007 and report the number, characteristics and treatment outcome of identified XDRTB cases.

METHODS

Study population

The results of drug susceptibility testing of all M tuberculosis complex isolates undertaken between 1995 and 2007 have been collated through the UK Mycobacterial Surveillance Network (MycobNet) collaboration. Results of drug susceptibility to the six main classes of drugs used to treat MDRTB (fluoroquinolones, serine analogues, aminoglycosides, capreomycin, p-aminosalicylic acid (PAS) and the thionamides) and other agents (clarithromycin, azithromycin, rifabutin, streptomycin and clofazimine) were analysed. Duplicate results from isolates were manually removed by using patient names, date of birth and address where available. It is, however, possible that a small number of duplicate records remain due to the limited amount of demographic information in the MycobNet database.

Definitions

MDRTB was defined as resistance to at least isoniazid and rifampicin, and XDRTB as resistance to at least isoniazid, rifampicin, a fluoroquinolone and one of three injectable second-line drugs (amikacin, kanamycin or capreomycin). First-line drugs in the UK include rifampicin, isoniazid, pyrazinamide and ethambutol.

Data collection

In addition to data on drug susceptibility collected through the MycobNet collaboration, we retrospectively contacted the reporting clinician to determine the outcome of treatment as well as additional clinical and demographic information on patients with XDRTB. With the exception of one recent XDRTB case, the information was collected more than 3 years after initial diagnosis. Strain typing information based on 15-loci mycobacterial interspersed repetitive units variable number tandem repeats (MIRU-VNTR) performed as described previously,7 was collated for all XDRTB cases to investigate the possibility of person to person transmission. MIRU-VNTR typing became available in 1999 and isolates from
cases diagnosed prior to this date were typed retrospectively where available.

**Statistical analysis**

Analysis of second-line drug susceptibility results among MDRTB cases was carried out to examine long-term trends and determine the extent of XDRTB. Proportions were calculated and, where appropriate, an extension of the Wilcoxon rank-sum test for trend across ordered groups was used to assess the statistical significance of trends.

**RESULTS**

Between 1995 and 2007, a total of 678 MDRTB cases were reported to the MycobNet collaboration, an average of 52 cases per year. The median age of the group was 32 years (interquartile range 26–43 years) and 59% (377/639 cases where gender was known) were male. Table 1 shows the proportion of MDRTB cases resistant to second-line antituberculosis drugs. Among MDRTB isolates, levels of resistance to amikacin, capreomycin, ciprofloxacin, cycloserine, ethionamide and PAS were 5.5, 3.4, 5.6, 5.1, 14.0 and 16.7%, respectively. Where tested, resistance to rifabutin and streptomycin was very high. Resistance to the first-line drugs, pyrazinamide and ethambutol was 28.0% and 36.1%, respectively.

**XDRTB cases**

Six XDRTB cases (0.9% of MDR cases) were identified during this period. Two further cases of XDRTB were reported in 2008. Of the eight cases, six were male and all were adults (table 2). Three cases were of white ethnic group and six were known to be born outside the UK. Five cases had pulmonary disease with or without extrapulmonary involvement, and six cases were not known or suspected to be HIV positive. All cases had isolates resistant to a variety of second-line drugs with a minimum resistance to five drugs. Five individuals died of tuberculosis within 3 years of diagnosis and three are still on treatment (including the two diagnosed in 2008). Strain typing data were available for five out of the eight XDRTB isolates; all five were distinguishable using 15-loci MIRU-VNTR. A search of the national strain typing database identified a limited number of MDRTB cases which shared indistinguishable MIRU-VNTR type with two of these cases. The 15-digit MIRU-VNTR code for these two isolates was 4245523325173353 and 224331432615324, also associated with a further 11 and 3 MDRTB cases, respectively. These MDRTB cases were reported from a geographically widespread area. Stored isolates from three cases could not be recovered. Lack of strain typing data prior to 2003 limits the interpretation of transmission in this context.

A further 12 MDRTB cases had resistance to at least three of the six second-line antituberculosis drugs, fulfilling the initial, but not the subsequently revised, definition for XDRTB.

**DISCUSSION**

The level of XDRTB in the UK remains low despite the occurrence of about 50 new MDRTB cases each year and an increase in the incidence of tuberculosis over the last two decades. Eight patients between January 1995 and October 2008 had drug susceptibility results consistent with the current definition of XDRTB. Five of the eight cases died of their disease.

The low levels of XDRTB in the UK compared with other European countries may reflect minimal incidence of second- and third-line drug resistance in the country of origin of the majority of non-UK-born tuberculosis patients. Alternatively, this may be due to high levels of appropriate clinical management of patients with MDRTB. Our finding of poor clinical outcome in these patients with XDRTB is consistent with previous studies where a large proportion of cases died of tuberculosis, especially among individuals co-infected with HIV. In contrast to the South African experience, our patient population had, as far as is known, low levels of HIV infection.

There was no evidence of transmission of XDRTB or from an MDRTB strain with the same MIRU-VNTR pattern, based on typing results. This cannot, however, be excluded as six cases were non-UK born and could have acquired the infection from an MDRTB or XDRTB case outside the UK. Due to the lack of strain typing data prior to 2003, we cannot exclude the possibility that some of the isolates identified prior to widespread typing were responsible for transmission. We were also unable to obtain detailed clinical information on other factors contributing to the death of these patients due to the retrospective nature of this study.

The poor outcome in these patients with XDRTB, however, suggests that UK clinicians should ensure that a package of care which includes directly observed treatment is available for all patients with MDRTB to prevent the development of XDRTB. The experience of most clinicians is likely to be limited, even in parts of the UK with a higher incidence of tuberculosis, given the small number of cases. As the management of these patients is complex, the use of second-line antituberculosis drugs, especially fluoroquinolones, kanamycin, amikacin and capreomycin, in patients infected with MDRTB strains should always be undertaken by those with appropriate experience and expertise.

The management of cases of MDRTB involves the choice of a combination of second-line antituberculosis drugs, and occasionally first-line agents, which should be based on drug susceptibility tests. It is sometimes necessary to start second-line treatment while awaiting these results. Our data suggest that certain drugs, such as rifabutin and clofazimine, are unlikely to be useful for empirical treatment in the UK in this situation. In addition, >60% of MDRTB isolates and three XDRTB cases were susceptible to ethambutol, a drug which has synergistic effects with others due to its action on the cell.

---

**Table 1** Second-line antituberculosis drug resistance among multidrug-resistant isolates of *M tuberculosis* complex, UK, 1995–2007

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Resistant/tested* (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoroquinolones</td>
<td>Ciprofloxacin</td>
<td>34/610 (5.6)</td>
</tr>
<tr>
<td></td>
<td>Moxifloxacin</td>
<td>1/24 (4.2)</td>
</tr>
<tr>
<td></td>
<td>Ofloxacin</td>
<td>1/26 (3.9)</td>
</tr>
<tr>
<td></td>
<td>Any fluoroquinolone</td>
<td>36/647 (5.6)</td>
</tr>
<tr>
<td>Serine analogues</td>
<td>Cycloserine</td>
<td>28/551 (5.1)</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>Amikacin</td>
<td>32/583 (5.5)</td>
</tr>
<tr>
<td></td>
<td>Kanamycin</td>
<td>1/24 (4.2)</td>
</tr>
<tr>
<td>Polypeptides</td>
<td>Capreomycin</td>
<td>20/592 (3.4)</td>
</tr>
<tr>
<td>Thionamides</td>
<td>Ethionamide</td>
<td>84/801 (14.0)</td>
</tr>
<tr>
<td></td>
<td>Prothionamide</td>
<td>2/5 (40.0)</td>
</tr>
<tr>
<td></td>
<td>Any thionamide</td>
<td>86/606 (14.2)</td>
</tr>
<tr>
<td>PAS</td>
<td>PAS</td>
<td>77/462 (16.7)</td>
</tr>
<tr>
<td>Others</td>
<td>Clarithromycin</td>
<td>70/587 (11.9)</td>
</tr>
<tr>
<td></td>
<td>Azithromycin</td>
<td>8/92 (8.7)</td>
</tr>
<tr>
<td></td>
<td>Streptomycin</td>
<td>327/638 (51.4)</td>
</tr>
<tr>
<td></td>
<td>Rifabutin</td>
<td>138/160 (86.3)</td>
</tr>
<tr>
<td></td>
<td>Clofazimine</td>
<td>33/94 (35.1)</td>
</tr>
</tbody>
</table>

*Where information on testing was available among a total of 678 isolates. PAS, p-aminosalicylic acid.
membrane of mycobacteria, allowing the use of this agent in such patients. Newer fluoroquinolones such as moxifloxacin should still be considered in the management of these patients as there is evidence that the efficacy of later-generation fluoroquinolones may be preserved, despite resistance to ciprofloxacin. The Peruvian study suggests that clinicians may also want to reinforce regimens with pyrazinamide and ethambutol with clarithromycin, clofazimine and rifabutin.

Where drug susceptibility information on these agents is available, our data suggest that these agents may have a role in the management of XDRTB.

This study is limited by the small number of cases of XDRTB reported. A further limitation relates to the lack of information on the long-term treatment outcome for all cases of MDRTB to allow a comparison with the patients with XDRTB. National surveillance is being developed to collect information on clinical outcome at 24 months to inform future analysis. As in other developed countries, not all cases of tuberculosis in the UK are culture confirmed. These data therefore represent the susceptibility results from those with a proven bacterial culture only. Nevertheless, this sample included all culture-confirmed cases and is unlikely to be affected by survival bias which many XDRTB studies may be prone to.

Despite the low incidence of MDRTB and XDRTB in the UK, this study found high case fatality among XDRTB patients. A recent postal survey by the British Thoracic Society (BTS) suggested that clinicians with no experience of managing MDRTB remain willing to treat these patients. Evidence from countries with high rates of drug resistance that have successfully tackled this problem suggests that an alternative approach is likely to be more successful. The BTS has recently been commissioned by the Department of Health to set up multidisciplinary tuberculosis teams (MDT) working in every area of England and Wales, together with an expert clinical advisory service to underpin and advise the MDTs as needed. In tandem with this, a group of UK clinicians have recently started an advisory service to underpin and advise the MDTs as needed. In England and Wales, together with an expert clinical advisory service to underpin and advise the MDTs as needed.

<table>
<thead>
<tr>
<th>Year</th>
<th>Sex</th>
<th>Age</th>
<th>Ethnicity and place of birth</th>
<th>Previous TB</th>
<th>Drug resistance additional to UK first-line agents*</th>
<th>Site of disease</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>Female</td>
<td>20–29</td>
<td>White, non-UK</td>
<td>No</td>
<td>Kan, Mox, Off, PAS, Strep</td>
<td>Pulmonary</td>
<td>Still on treatment</td>
</tr>
<tr>
<td>2008</td>
<td>Male</td>
<td>20–29</td>
<td>Black African, non-UK</td>
<td>Yes</td>
<td>AK, Cap, Eth, Kan, Off, Pro, Strep</td>
<td>Pulmonary</td>
<td>Still on treatment</td>
</tr>
<tr>
<td>2003</td>
<td>Male</td>
<td>30–39</td>
<td>White, UK</td>
<td>No</td>
<td>Cap, Cip, Eth</td>
<td>Pulmonary</td>
<td>Still on treatment</td>
</tr>
<tr>
<td>2002</td>
<td>Male</td>
<td>30–39</td>
<td>White, non-UK</td>
<td>No</td>
<td>Cap, Cip, Cla, Clo, Cyc, RB</td>
<td>Cervical Lymph Node</td>
<td>Died of TB</td>
</tr>
<tr>
<td>1999</td>
<td>Male</td>
<td>20–29</td>
<td>Indian subcontinent, non-UK</td>
<td>Yes</td>
<td>AK, Cap, Cip, Cla, Clo, Eth, RB</td>
<td>Pulmonary</td>
<td>Died of TB</td>
</tr>
<tr>
<td>1997</td>
<td>Male</td>
<td>40–49</td>
<td>Indian subcontinent, non-UK</td>
<td>Yes</td>
<td>AK, Cap, Cip, Cla, Clo, Cyc, PAS, Strep</td>
<td>Pulmonary</td>
<td>Died of TB</td>
</tr>
<tr>
<td>1997</td>
<td>Male</td>
<td>80–89</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Cap, Cip, Cyc, Strep</td>
<td>Abdominal</td>
<td>Died of TB</td>
</tr>
<tr>
<td>1995</td>
<td>Female</td>
<td>50–59</td>
<td>Unknown</td>
<td>Unknown</td>
<td>AK, Cip, Cla, RB, Strep</td>
<td>Pulmonary</td>
<td>Died of TB</td>
</tr>
</tbody>
</table>

*First-line drugs in the UK include rifampicin, isoniazid, pyrazinamide and ethambutol. AK, amikacin; Cap, capreomycin; Cip, ciprofloxacin; Cla, clarithromycin; Clo, clofazimine; Cyc, cycloserine; Eth, ethionamide; Kan, kanamycin; Off, ofloxacin; Pro, prothionamide; RB, rifabutin; Strep, streptomycin; TB, tuberculosis.

REFERENCES

Pulmonary puzzle

Box 1 Laryngeal obstruction or stenosis: aetiology and reported anatomical sites

Supraglottic
- Carcinomas (85% squamous)
- Relapsing polychondritis
- Mucous membrane pemphigoid
- Diphtheria
- Epiglottitis

Transglottic
- Carcinomas
- Papillomatosis
- Sarcoidosis
- Tuberculosis
- Perichondritis and radionecrosis
- Fracture

Subglottic
- Carcinomas
- Wegener granulomatosis
- Intubation injury

Other
- Carcinoid, amyloid, Kaposi sarcoma, metastases, gastrooesophageal reflux.

REFERENCES
Extensively drug-resistant tuberculosis in the UK: 1995 to 2007


Thorax 2009 64: 512-515 originally published online March 23, 2009
doi: 10.1136/thx.2008.108712

References

This article cites 12 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/64/6/512#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Drugs: infectious diseases (968)
HIV/AIDS (194)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/